We show that limiting iron availability in C. elegans through frataxin silencing or the iron chelator bipyridine, similar to hypoxia preconditioning, protects against hypoxia-, age-, and proteotoxicity-induced neuromuscular deficits. Mechanistically, our data suggest that the beneficial effects elicited by frataxin silencing are in part mediated by counteracting ferroptosis, a form of non-apoptotic cell death mediated by iron-induced lipid peroxidation.
Thursday, April 27, 2023
Mitochondria hormesis delays aging and associated diseases in Caenorhabditis elegans impacting on key ferroptosis players
Mitochondria hormesis delays aging and associated diseases in Caenorhabditis elegans impacting on key ferroptosis players. Schiavi, Alfonso et al., iScience, Volume 26, Issue 4, 106448. doi:10.1016/j.isci.2023.106448
Monday, April 24, 2023
Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation - Scientific guideline
First published: 21/04/2023, Consultation dates: 21/04/2023 to 30/09/2023; EMA/CHMP/564424/2021
This reflection paper is intended to reflect the current thinking of EMA's Committee for Medicinal Products for Human Use (CHMP) on single-arm trials (SATs) that are submitted as pivotal evidence for establishing efficacy in a marketing authorisation application. The reflection paper discusses considerations in relation to the design, planning, conduct, analysis and interpretation of results derived from single-arm trials. It is applicable across different therapeutic areas, including for rare diseases.
Wednesday, April 19, 2023
The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases
He, R., Liu, B., Geng, B. et al. The role of HDAC3 and its inhibitors in regulation of oxidative stress and chronic diseases. Cell Death Discov. 9, 131 (2023). doi:10.1038/s41420-023-01399-w
In this review, we comprehensively summarize the knowledge of the relationship of HDAC3 with mitochondria function and metabolism, ROS-produced enzymes, antioxidant enzymes, and oxidative stress-associated transcription factors. We also discuss the role of HDAC3 and its inhibitors in some chronic cardiovascular, kidney, and neurodegenerative diseases.
Saturday, April 15, 2023
Auditory neuropathy in mice and humans with Friedreich ataxia
Rance, G., Carew, P., Winata, L., Sale, P., Delatycki, M. and Sly, D. (2023), Auditory neuropathy in mice and humans with Friedreich ataxia. Ann Clin Transl Neurol. https://doi.org/10.1002/acn3.51777
This study found degenerative changes in auditory structure and function in YG8Pook/J mice, indicating that auditory measures in these animals may provide a model for testing Friedreich ataxia treatments. In addition, auditory steady-state response findings in a clinical population suggested that these scalp-recorded potentials may serve as an objective biomarker for disease progress in affected individuals.
Sunday, April 9, 2023
Butyrate prevents visceral adipose tissue inflammation and metabolic alterations in a mouse model of Friedreich's ataxia
TURCHI R, SCIARRETTA F, TIBERI M, et al. Butyrate prevents visceral adipose tissue inflammation and metabolic alterations in a mouse model of Friedreich's ataxia. bioRxiv; 2023. DOI: 10.1101/2023.04.06.535845.
In conclusion, this study identified vWAT as an important player in the onset of metabolic complications typical of FA and suggests butyrate as safe and promising adjuvant tool to treat metabolic complications in FA.
Saturday, April 8, 2023
Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich’s Ataxia
Elisabetta Indelicato, Alexander Kirchmair, Matthias Amprosi, Stephan Steixner, Wolfgang Nachbauer, Andreas Eigentler, Nico Wahl, Galina Apostolova, Anne Krogsdam, Rainer Schneider, Julia Wanschitz, Zlatko Trajanoski, Sylvia Boesch, Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich’s Ataxia, Human Molecular Genetics, 2023;, ddad051, doi:10.1093/hmg/ddad051
Our findings reflect a double hit in the pathophysiology of FRDA: a transcriptional/translational issue, and a profound mitochondrial failure downstream. Leptin upregulation in the skeletal muscle in FRDA may represent a compensatory mechanism of mitochondrial dysfunction, which is amenable to pharmacological boosting. Skeletal muscle transcriptomics is a valuable biomarker to monitor therapeutic interventions in FRDA.
Thursday, April 6, 2023
Efficiency of a 3-week multicomponent rehabilitation on improving the function in a patient with Friedreich's ataxia: A case report
Samardžić Vesna; Vojnosanitetski pregled 2023, vol. 80, iss. 2, pp. 182-187. DOI:10.2298/VSP220209027S
We present a 26-year-old female with FA who had severe truncal and limb ataxia, speech difficulty, and poor walking ability. During the three-week rehabilitation, an individually tailored physical therapy program based on PNF stabilization techniques was applied. The implemented rehabilitation program resulted in an overall functional improvement. The reduction in ataxia was registered according to the Scale for the Assessment and Rating of Ataxia (SARA). The Functional Independence Measure (FIM) instrument - a component of locomotion, revealed greater independence in walking. Conclusion. A rehabilitation program based on PNF stabilization techniques may reduce ataxia and improve walking ability in patients with FA.
Thursday, March 30, 2023
Gene Suppression Therapies in Hereditary Cerebellar Ataxias: A Systematic Review of Animal Studies
Santos C, Malheiro S, Correia M, Damásio J. Gene Suppression Therapies in Hereditary Cerebellar Ataxias: A Systematic Review of Animal Studies. Cells. 2023; 12(7):1037. https://doi.org/10.3390/cells12071037
In FRDA, only the suppression efficacy of the electroporation of the clustered regularly interspaced short palindromic repeats associated with Cas9 enzyme system (CRISPR-Cas9) system was tested and confirmed. Conclusion: The literature reviewed suggests that GSTs are well tolerated and effective in suppressing the targeted proteins, improving neuropathological features and the motor phenotype in vivo. Nonetheless, there is no guarantee that these results are free of bias. Moreover, further investigation is still needed to clarify the GST effect on HCAs such as FRDA, SCA6 and SCA2.
Traitement somatosensoriel proprioceptif et tactile chez les personnes atteintes d’ataxie de Friedreich, une étude d’imagerie par résonance magnétique fonctionnelle
Virginie Destrebecq, Valérie Martinet, Antonin Rovai, Nicolas Trotta, Gilles Naeije, Traitement somatosensoriel proprioceptif et tactile chez les personnes atteintes d’ataxie de Friedreich, une étude d’imagerie par résonance magnétique fonctionnelle, Volume 8063, Issue 100, 04/2023, Pages S1-S210, ISSN 0035-3787, doi: 10.1016/j.neurol.2023.01.629
Discussion
Ces paradigmes d’IRMf capturent la dichotomie entre les déficiences tactiles et proprioceptives chez les personnes atteintes de FRDA. L’altération proprioceptive prédominante rappelle le patron lié au vieillissement.
Conclusion
L’âge et la FRDA pourraient se potentialiser et rendre les déficits de perception tactile cliniquement pertinents.
Clinically meaningful metrics of speech in neurodegenerative disease: Quantification of speech intelligibility and naturalness in ataxia
Clinically meaningful metrics of speech in neurodegenerative disease: Quantification of speech intelligibility and naturalness in ataxia
Adam P Vogel, Paul Maruff, Hannah Reece, Hannah Carter, Geneieve Tai, Benjamin G Schultz, Louise Corben, Martin B Delatycki, Athanasios Tsanas; medRxiv 2023.03.28.23287878; doi:10.1101/2023.03.28.23287878
We demonstrate a subset of measures are strongly associated with all four clinical scales. Objective speech data replicated expert assessments of naturalness and intelligibility. These scores represent a lower level of variability than observed between subjective listener ratings. Findings provide evidence there are specific objective markers of speech that change over time and reflect clinical aspects of the disease. Discussion: The use of a large dataset yielded a speech assay capable of accurately approximating expert listener ratings of key clinical aspects of dysarthria severity. Distinct but complementary subsets align with disease severity and speech related quality of life.
Subscribe to:
Posts (Atom)
